Showing 1531-1540 of 5771 results for "".
- Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZOhttps://modernod.com/news/harrow-announces-transitional-pass-through-reimbursement-status-for-iheezo/2481462/Harrow announced that the Centers for Medicare & Medicaid Services (CMS) has approved transitional pass-through reimbursement status for IHEEZO (chloroprocaine hydrochloride ophthalmic gel, 3%), which is indicated for ocular surface anesthesia. Beginning April 1, 2023, and
- Ophtec Celebrates 40 Year Anniversary with New Brand Identityhttps://modernod.com/news/ophtec-celebrates-40-year-anniversary-with-new-brand-identity/2481460/Ophtec is celebrating its 40th anniversary in 2023 and launching a new brand identity, "Modernized and fit for the future." Ophtec was founded in 1983 by the Dutch ophthalmologist Prof. Dr. Jan Worst, also known as the inventor of the world’s first Iris fi
- Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meetinghttps://modernod.com/news/kiora-pharmaceuticals-announces-the-acceptance-of-three-abstracts-at-the-2023-arvo-annual-meeting/2481458/Kiora Pharmaceuticals announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, April 23-27, 2023. Further results from each of these three studies will be reported at the conference.<
- TearRestore Announces Positive Clinical Trial Results for Patients with Dry Eye Diseasehttps://modernod.com/news/tearrestore-announces-positive-clinical-trial-results-for-patients-with-dry-eye-disease/2481456/TearRestore announced positive toptine results of a study conducted by the University of Colorado titled, “The Effect of Warm Compress Therapy on Dry Eye Disease,” using the TearR
- Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meetinghttps://modernod.com/news/phase-12a-results-of-lineage-cells-retinal-pigment-epithelium-cell-transplant-therapy-to-be-featured-at-arvo-annual-meeting/2481451/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.
- Harrow Announces Appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilancehttps://modernod.com/news/harrow-announces-appointment-of-mark-mannebach-phd-rph-as-head-of-regulatory-affairs-and-pharmacovigilance/2481449/Harrow announced the appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the company’s portfolio of new and existing products. Dr. Mannebach
- EyeBio Announces First Asset in Pipeline of Retinal Disease Treatments and Appoints New Members to Executive Teamhttps://modernod.com/news/eyebio-announces-first-asset-in-pipeline-of-retinal-disease-treatments-and-appoints-new-members-to-executive-team/2481448/Eyebiotech Limited announced several appointments to its executive team and announced details on Restoret, the first asset in a pipeline of multi-specific agonist antibodies. EyeBio announced the following appointments to the senior leadership team: Anthony P. Adami
- Vialase Announces Positive Results of First-in-Human Study of Femtosecond Laser Image-Guided High Precision Trabeculotomyhttps://modernod.com/news/vialase-announces-positive-results-of-first-in-human-study-of-femtosecond-laser-image-guided-high-precision-trabeculotomy/2481443/ViaLase announced results of the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with ViaLase technology. The results, which the company says indicate FLigHT's potential as a safe and effective treatment option for primary open angle glau
- Aldeyra Therapeutics Announces Positive Topline Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-results-from-12-month-safety-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease/2481437/Aldeyra Therapeutics announced topline results from a 12-month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug in dry eye disease patients. The primary endpoints of treatment-related serious adverse events in ocular safet
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si